

Recién nacido con SQTl – 2016





Dr. Luciano Pereira

RN sexo masculino, 1 día de vida; sin antecedentes maternos (madre médica, 30 años); presenta taquicardia fetal en observación ecográfica obstétrica (entre 250-300 x') y se decide cesárea. El BB está en UTI con soporte de O2, FC 125 x' después de adenosina. Corazón estructuralmente normal por ecocardio. Foramen oval permeable e hipertensión pulmonar probablemente leve.

QT largo.

Saludos.

Luciano Pereira



OPINIONES DE COLEGAS

Usaría un beta bloqueante, si es posible Nadolol. No está claro si fue una TSV o TdP

Mario González

Padrão típico LQT 3 MUITO PREOCUPANTE

O que caracteriza esta variante (2% de todas) é o prolongamento do segmento ST em virtude da entrada persistente de Na⁺ tardio em fase 2 o que condiciona aparecimento tardio da T. O diagnóstico intraútero desta variante é cada vez mais frequente (1)

Horigome H, Nagashima M, Sumitomo N, Yoshinaga M, Ushinohama H, Iwamoto M, Shiono J, Ichihashi K, Hasegawa S, Yoshikawa T, Matsunaga T, Goto H, Waki K, Arima M, Takasugi H, Tanaka Y, Tauchi N, Ikoma M, Inamura N, Takahashi H, Shimizu W, Horie M. Clinical characteristics and genetic background of congenital long-QT syndrome diagnosed in fetal, neonatal, and infantile life: a nationwide questionnaire survey in Japan. *Circ Arrhythm Electrophysiol.* 2010 Feb;3(1):10-7

Andrés R. Pérez Riera

Por morfología del ST-T impresiona LQT3. ¿Antiarrítmico IC? Análisis genético!!

Oscar Pellizzón

Si, la morfología parece QT largo 3. Primero hay que ver cómo evoluciona. No está claro que arritmia tuvo. No parece TdP ya que terminó con adenosina.

Feliz Navidad!!!

Mario González

LQT3 VARIANT CHARACTERISTICS

Dr Andrés Ricardo Pérez Riera

Professor da Faculdade de Medicina do ABC.

Name: LQT3

Affected gene: SCN5A

Chromosome: **3**. Mapped for the first time in 1994 by Jiang et al (1). Later a p21-24 mutation was detected in the SCN5A gene, in chromosome 3 by Wang et al (2).

Mutation: 3p21-24

OMIM number: 600163

Affected channel: Na⁺channel

Affected AP phase: Plateau, dome or phase 2.

Transmission: Autosomal dominant. In 1998, Dr. Silvia Priori et al, showed the first evidence that the Romano-Ward syndrome (RWS) could be recessive (3). Note: all LQT3 correspond to RWS; however, it is not so in reverse, because RWS could be of the LQT4 type, LQT2 7 (HERG) and LQT5 21q22.1 (Mink) (4).

Triggers: Sleep, night vagotonia. Most of the events occur during sleep or in rest (61%) (5). Unlike in LQT1, they occur almost exclusively during strain or stress.

Phenotype

a) Clinical: there are reports that LQT3 could be associated to syndactyly (6);

b) Electrocardiographic:

1) Heart rate: tendency to bradycardia related to age and in some cases, decrease during rising efforts has been observed. When HR increases, the QT interval shortens more in LQT3 than in LQT1 and LQT2;

2) PR interval: usually normal. However, we found a family with short PR.

3) ST segment: significant prolongation. Consequence: late appearance of T wave. The deltaKPQ mutation causes a small and persistent inflow of Na⁺ in phase 2 with late reopening, which explains QT interval prolongation.

4) QT interval dependence of heart rate: significant.

5) QT interval: In the LQT3 variant it is usually longer than in LQT1 and LQT2.

6) U wave: it could be prominent in many cases as a consequence of longer repolarization of the M cell. It increases in bradycardias and in pauses and it may present alternating polarity.

7) Accentuated QT interval dispersion (7). In turn, this fact is a risk marker for the appearance of arrhythmias (8).

Response to exercise stress test

Normalization of ventricular repolarization alterations may be occasionally observed. In the LQT1 and LQT2 variants, it may trigger tachyarrhythmic events.

Relative incidence: When compared to LQT1 and LQT2, the least frequent 1%.

Number of events: Less than in LQT1 and LQT2.

Lethality of events: Greater than in LQT1 and LQT2.

Accumulative lethality: Similar in the three variants.

Alleles:

- 1) Brugada disease.
- 2) Mixed forms with Brugada disease.
- 3) True idiopathic ventricular fibrillation.
- 4) Lenègre disease.

Brugada disease:

This variant is considered allelic to Brugada disease. For this reason it is said that it is the “mirror image” of LQT3, because both affect the alpha subunit of the Na⁺ channel and are autosomal dominant. Approximately 2/3 of Brugada cases are sporadic (Brugada syndrome) and only 1/3 present autosomal dominant inheritance with positive family history. The genetic proof is possible in only 15% to 20% of the cases (Brugada disease).

Mixed forms with Brugada disease:

The Na⁺ channel in the SCN5A gene is involved both in Brugada disease and in LQT3. These syndromes lead to opposite effects on the channel. Thus, in Brugada syndrome the mutation causes Na⁺ inflow reduction, while in LQT3 it is associated to a gain in function with low inflow of the cation in phase 2.

Investigations indicate the existence of mixed forms characterized by overlapping phenotypical manifestations with prolonged QTc interval and ST segment elevation from V1 to V2 or V3.

Flecainide is a drug used to unmask Brugada disease, and it may cause ST segment elevation in some patients with LQT3 (9).

True idiopathic ventricular fibrillation (IVF):

True IVF, the LQT3 variant and Brugada disease affect the same SCN5A gene, hold the same OMIM number (600163) and the same locus (3p21-p34).

Drugs that improve repolarization

- 1) Mexiletine
- 2) Flecainamide

1) Mexiletine: class 1B antiarrhythmic agent, of the lidocaine-like type, which is very efficient to shorten QT only in LQT3. This variant presents a T wave of late appearance by ST segment prolongation as a consequence of the permanent inflow of Na⁺. In these patients, mexiletine significantly shortens QTc, preventing the appearance of TdP. Remarkably, the drug does not shorten long QT in congenital long QT syndrome affecting the K⁺ channel (HERG defect of the K⁺ channel), called LQT2(10, 11). The drug does not shorten long QT of the congenital long QT syndrome affecting the K⁺ channel (HERG defect of the K⁺ channel) or LQT2 (12).

2) Flecainide: This drug has been proposed and it seems promising for the oral treatment in LQT3 in patients with the DeltaKPQ mutation in the SCN5A gene. It causes block in the Na⁺late inflow (13).

Drugs that worsen repolarization:

Beta blockers have a protective effect in LQT1 and LQT2, but may trigger TdP in LQT3 (14).

Drug that resembles the LQT3 variant

The drug known as ATX-II causes the increase in late Na⁺inflow, I_{Na}, and may resemble the LQT3 situation prolonging ST segment duration and causing late T wave and long QT. This ST prolongation by increase in Na⁺late inflow seems more intense in M cells than in endocardial and epicardial cells, thus increasing repolarization dispersion. This greater increase in M cells is caused by them having a greater late Na⁺channel (15).

Treatment

LQT1 and LQT2 benefit more with beta blockers. In LQT3 these drugs could be harmful. This is the variant that best responds to pacemakers. Some patients may present sudden pauses in sinus rhythm that exceed 1.2 seconds, not preceded by alterations in heart rate. They may be important at the onset of arrhythmias in patients with LQTS and frequently precede the onset of TdP, pointing the indication of pacemakers as the therapeutic choice. Holter may possibly record the characteristics of the onset of TdP runs, i.e. if they are bradycardia-dependent or if it helps in the choice of the therapeutic method to be used. Thus, VT triggered by pauses or bradyarrhythmias have the indication of permanent pacemaker. Several publications advocate pacemaker implantation at rates between 70 and 90 bpm, as treatment of choice in the cases in which inappropriate bradycardia is the main factor generating tachyarrhythmia episodes. Permanent pacemaker is clearly indicated in those patients with inappropriate bradycardia and evidence of pause-dependent or bradycardia-dependent malignant arrhythmia. The resource should not be made as a single therapy and without supplementing antiadrenergic therapy. In brief, pacemakers are indicated when there is proof that TdP are bradycardia- or pause-dependent. Rates above 110 beats per minute may lead to dilated cardiomyopathy.

The implant of permanent pacemaker at greater rates could be more beneficial in patients carriers of LQT3, because the latter presents a higher risk of arrhythmias at low rates when compared to HERG LQT2. With the increase in HR there is a greater QT shortening in LQT3 than in LQT2 (16).

Cardioverter defibrillator should be considered in those patients with recurrent arrhythmias in spite of a proper antiadrenergic therapy. Some genetic subtypes as LQT3 may not respond to antiadrenergic therapy or even respond negatively, requiring an ICD (17).

Up to 10% of asymptomatic patients of any LQTS variety present SCD or cardiorespiratory arrest in the first episode of arrhythmia, particularly the carriers of variant 3 that have a

lower number of events, in spite of a greater mortality in every episode. Because of this high risk, the treatment is advised in all asymptomatic patients with LQTS, except for the family members carriers of genetic anomalies, asymptomatic, older than 20 years and with normal QTc interval (18).

A very useful tool for decision making in the therapeutic choice is Holter recording because it allows:

1) To record occasionally the characteristics of the onset of TdP runs; i.e. if they are bradycardia-dependent, a particularly frequent fact in variant 3, which helps in the choice of the therapeutic method to be used. *Thus, VT triggered by pauses or bradyarrhythmias have an indication of permanent pacemaker at a lower rate.*

2) T wave alternans: this parameter is an electric instability and regional heterogeneity of repolarization marker and identifies the patients with LQTS of high risk. These patients have an increased risk of cardiac events; however, T wave alternans does not constitute an independent risk marker (19).

The initial therapy of choice is overdrive atrial pacing. Several publications advocate pacemaker implantation at rates between 70 and 90 bpm, as treatment of choice in the cases in which it is verified that inappropriate bradycardia generates pause- or bradycardia-dependent malignant tachyarrhythmic events. There has been reports about the use for pause prevention, of a pacemaker algorithm (rate smoothing), which increases temporarily the pacemaker rate when the following occur:

- 1) Spontaneous extrasystoles;
- 2) Decrease of HR below 18% of base rate;
- 3) Pauses related to change in T-U and;
- 4) Recurrent pauses that induce TdP.

The rate smoothing algorithm seems to be a good tool to prevent TdP in LQTS (20).

Pacemaker rates above 110 beats per minute may lead to dilated cardiomyopathy.

Permanent pacemaker implantation at higher rates may be of greater benefit in patients carriers of the LQT3 variant, because this has a greater risk of arrhythmias at low rates (VAGOTONIA) when compared to the HERG LQT2 variant. With the increase of HR, there is a greater QT shortening in the LQT3 variant than in LQT2 (16).

Khan suggests that any diagnosed and asymptomatic patient who is younger than 40 years should be treated (21). In the pharmacological therapeutic arsenal in LQT3 we have 2 drugs: mexiletine and flecainide.

Mexiletine Mexitil^R (Boeringer Ingenheim) orally with capsules: 100 and 200 mg. Posology: 3 times per day, maximal 1200 mg x day with (antiarrhythmic agent, blocker of Na⁺channels of the IB class), decreases the QT interval and normalizes T wave morphology only in the LQT3 variant. It is not the same in patients with LQT2 and LQT1. This LQTS variant is secondary to a genetic alteration that affects the Na⁺channel located

in chromosome 3p21, specifically in the alpha subunit of the SCN5A channel, the same one affected in Brugada syndrome. In these patients, mexiletine significantly shortens QTc, preventing the appearance of TdP. The drug does not shorten the long QT interval in congenital long QT syndrome affecting the K⁺ channel (HERG defect of the K⁺ channel) or LQT2 (6). Class IB drugs have a rapid kinetics of union and release and thus, they only reduce V_{max} slightly, not affecting the QRS complex and the JT interval. They do not modify or shorten AP duration. The Na⁺ channel block with oral flecainide has been proposed for the treatment of the LQT3 variant. In some LQT3 patients, the drug causes Brugada-like ST segment elevation (intermediary phenotype) (12).

Thirteen patients carriers of the LQT3 variant, were tested with IV flecainamide in the advised dose for the pharmacological test for Brugada syndrome. In 12, QTc interval shortening was observed and in 6 from the 13, ST segment elevation from V1 to V3 ≥ than 2 mm (9).

In the SCN5A gene, the Na⁺ channel mutation DeltaKPQ causes LQT3 and the 1795insD mutation causes both Brugada syndrome and LQT3. The latter mutation, with the administration of flecainide, in a use-dependent mode, delays 4 times the recovery from the inactive state to emphasize the intermediary inactivation. Both mutation with the use of flecainide cause changes in the inactivation behavior from the closed state, with rapid and intermediary inactivation (22).

A low dose of oral flecainide shortens the QTc interval, and normalizes the T wave repolarization pattern in patients with the LQT3 variant, with DeltaKPQ mutation of SCN5A. The DeltaKPQ mutation presents repetitive reopenings of the Na⁺ channel and a slow and prolonged inflow current of the cation in phase 2 (23). This current manifests in ECG by QT interval prolongation at the expense of the ST segment and late appearance of T wave. Flecainide acting on the Na⁺ with the DeltaKPQ mutation, causes preferential block in the late Na⁺ inflow with slow recovery, which explains QT interval shortening in the LQT3 variant (24).

Thus, oral flecainide is a promising therapeutic agent for LQTS patients with the DeltaKPQ mutation of SCN5A in the Na⁺ channel. It was verified that only flecainide (and not lidocaine) corrects the LQT3 variant phenotype in carriers of the DG mutation.

These results show that this mutation provides a unique pharmacological response in the expression of channels, and it is known that the block of DG channels by flecainide acts on the C-terminal of the alpha subunit of the Na⁺ channel by flecainide/channel interaction. There are intermediary phenotypes.

References

1) Jiang C, Atkinson D, Towbin JA, et al. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. *Nat Genet* 1994; 8:141-147.

- 2) Wang Q, Shen J, Splawski I, et al. SCN5A mutation associated with an inherited cardiac arrhythmia, long QT syndrome *Cell* 1995; 80:805-811.
- 3) Priori SG, Schwartz PJ, Napolitano C, et al. A recessive variant of the Romano-Ward long QT syndrome? *Circulation* 1998; 97:2420-2425.
- 4) Priori SG, Barhanin J, Hauer RNW, et al: Genetic molecular basis of cardiac arrhythmias: impact on clinical management. *Circulation* 1999; 99:518.
- 5) Zareba W, Moss AJ, Schwartz PJ. et al: Influence of genotype on the clinical course of the long QT syndrome. International Long-QT syndrome Registry Research Group. *N Engl J Med* 1998; 339:960-965.
- 6) Marks ML, Whisler SL, Clericuzio C. et. al. A new form of long QT syndrome associated with syndactily. *J Am Coll Cardiol* 1995; 25:59-61.
- 7) De Ambroggi L, Negroni MS, Monza E, et al: Dispersion of ventricular repolarization in the long QT syndrome. *Am J Cardiol* 1991; 68:614-620.
- 8) Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. *Br Heart J* 1990; 63:342-344.
- 9) Cerrone M, Crotti L, Faggiano G, De Michelis V, Napolitano C, Schwartz PJ, Priori SG. Long QT syndrome and Brugada syndrome: 2 aspects of the same disease? *Ital Heart J* 2001; 2:253-257.
- 10) Mos AJ, Zareba W, Benhorin J, et al. ECG T-wave pattern in genetically distinct forms of the hereditary long QT syndrome *Circulation* 1995; 92:2929-2934.
- 11) Shimizu W, Antzelevitch C: Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of long QT syndrome 1997; 33:307-313.
- 12) Priori SG, Napolitano C, Paganini V, et al: molecular biology of QT long syndrome; Impact on management *Pacing Clin Electrophysiol* 20:2052-2057-1997.
- 13) Nagatomo T, January CT, Makielski JC. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. *Mol Pharmacol* 2000; 57:101-107.
- 14) Priori SG, Napolitano C, Schwartz PJ A. Molecular basis for the therapy of the long QT syndrome. *Arch Mal Coeur Vaiss* 1996; 89:1185-1187.
- 15) Eddlestone GT, Zygmunt AC, Antzelevitch C. Larger late sodium current contributes to the longer action potential of the M cell in canine ventricular myocardium [abstract]. *Pacing Clin Electrophysiol* 1996; 19:II-569.
- 16) Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na⁺ channel blockade and to increases in heart rate. Implications for gene-specific therapy. *Circulation* 1995; 92:3381-6.

- 17) Wilde AA. Is there a role for implantable cardioverter defibrillators in long QT syndrome? J Cardiovasc Electrophysiol 2002; 13:S110-113.
 - 18) Moss AJ. Clinical management of patients with the long QT syndrome: drugs, devices, and gene-specific therapy. PACE 1997; 20: 2058-2060.
 - 19) Zareba W, Moss AJ, le Cessie S, Hall WJ. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol 1994; 23:1541-1546.
 - 20) Li C, Hu D, Qin X, et al. Clinical features and management of congenital long QT syndrome: a report on 54 patients from a national registry. Heart Vessels. 2003;19:38-42.
 - 21) Khan IA. Long QT syndrome: diagnosis and management. Am Heart J 2002;143:7-14.
 - 22) Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 2000; 102:945-947.
 - 23) Viswanathan PC, Bezzina CR, George AL Jr, Roden DM, Wilde AA, Balser JR. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation 2001; 104:1200-1205.
 - 24) Windle JR, Geletka RC, Moss AJ, Zareba W, Atkins DL. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A: DeltaKPQ mutation. Ann Noninvasive Electrocardiol. 2001; 6:153-158.
-

Contando cuadritos calculo un QTc de como 500 msec.

Puede todavia acortarse porque el QT es mas largo en los recién nacidos (0).

El echo de que el bebe no tuvo torsade de pointes a pesar de la pausa producida por la adenosina es importante.

Adenosina "sabe" provocar torsade de pointes (1,2). Tanto asi que por muchos años nosotros usábamos la adenosina (infundida durante ritmo sinusal para diagnosticar syndrome de QT largo en pacientes con QT no-diagnostico (3). Dejamos de hacer esa prueba únicamente cuando encontramos una prueba mejor (4-6).

Es importante, igual que urgente, decidir que tipo de QT largo tiene el bebe. El electrocardiograma SUGIERE LQT3 pero en bebes ese ejercicio no funciona tan bien como en adultos. Ver el electrocardiograma de los papas y hermanos es importante y urgente. Igualmente importante y urgente es hacer el analisis genético. Porque si de

verdad se trata de LQT3 este bebe podría ser tratado con flecainida (7) o mexiletina (8). Nosotros usamos ranolazine para LQT3 (9) pero esa medicina no se ha usado en niños. Por otro lado, flecainida podría ser desastrosa para LQT2 porque flecainida es también un IKr blocker.

Mientras se decide el genotipo empezaría beta-bloqueadores con cuidado. La relación de LQT3 con beta-bloqueadores ha dado muchas vueltas. De que ayudan hasta que perjudican. Wilde acaba de publicar que beta-bloqueadores no son tan malos compensábamos para LQT3 (10). Parecido a lo que dijo alguna vez un presidente Mexicano sobre las relaciones con Estados Unidos: *Estas relaciones, ni nos benefician, ni nos perjudican, sino todo lo contrario.*

Sami Viskin

Referencias:

0. Schwartz PJ, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med.1998;338:1709
1. Celiker A, et al. Adenosine induced torsades de pointes in a child with congenital long QT syndrome. Pacing Clin Electrophysiol.1994;17:1814
2. Wesley RC, Jr., Turnquest P. Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome. Am Heart J.1992;123:794).
3. Viskin S, et al. Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J.2006;27:469
4. Viskin S, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955
5. Adler A, et al. The phenomenon of "QT stunning": the abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9:901
6. Chorin E, et al. Diagnostic value of T-wave morphology changes during "QT stretching" in patients with long QT syndrome. Heart Rhythm.2015;12:2263
7. Benhorin J, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation.2000;101:1698
- 8.Mazzanti A, others, Napolitano C, Priori SG. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. J Am Coll Cardiol. 2016;67:1053.
9. Chorin E, others, Viskin S. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Circ Arrhythm Electrophysiol.2016;9
- 10.Wilde AA, Moss AJ, Kaufman ES, et al. Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. Circulation.2016;134:872

Queridos colegas del Foro. ¿cómo están, la pasaron bien anoche (Navidad)? Les escribo para contarles que acaba de ser publicado en la prestigiosa revista *Europace* (Hohmann S, Rudic B, Konrad T, Duncker D, König T, Tülümen E, Rostock T, Borggreffe M, Veltmann C. Systematic ajmaline challenge in patients with long QT3 syndrome caused by the most common mutation: a multicentre study *Europace*. 2016 Dec 2. pii: euw214. [Epub ahead of print]) un artículo relacionado al RN que nos presentó ayer Luciano Pereira de Ciudad del Este Paraguay.

Se han descrito síndromes de superposición del LQT3 y del síndrome de Brugada (BrS). La identificación de pacientes con un fenotipo superpuesto es crucial antes del inicio de los fármacos antiarrítmicos Clase I para el tratamiento del LQT3. El objetivo de este estudio fue elucidar la respuesta a la ajmalina y desenmascarar el fenotipo Brugada en pacientes con LQT3 causado por la mutación más común, SCN5A-E1784K. Se incluyeron 23 sujetos en el estudio de familias estudiadas en centros de referencia terciarios diagnosticados con LQT3 causado por la mutación SCN5A-E1784K. Además del tratamiento clínico de rutina, fue realizada la prueba de ajmalina. Del total de los 23 sujetos (11 mujeres, con edad media 27 ± 14 años) de 4 familias no relacionadas con una historia familiar de MCS y el diagnóstico familiar de la mutación SCN5A-E1784K se sometieron a la prueba de ajmalina y estudio genético.

Se encontró que 16 (9 mujeres) eran portadores heterocigotos de la mutación SCN5A-E1784K y la prueba con ajmalina resultó positiva en 12 de los 16 (75% de los casos) portadores de mutación, pero fue negativa en todos los no portadores.

Después de la prueba de ajmalina, se observó un acortamiento significativo del intervalo JT (JTc) en los portadores de mutación. El intervalo basal JTc fue significativamente más largo en los portadores de mutación con una prueba de ajmalina positiva en comparación con aquellos con la prueba negativa. Acuérdense que el intervalo JT-JTc se extiende desde el punto J al fin de la onda T. Este parámetro hasta ahora se usa para los casos con QT prolongado con QRS ancho con 120ms o más es decir BCRD, BCRE WPW y disturbio de conducción intraventricular no específico. Como el QTc-QTc incluye la sístole eléctrica es decir la despolarización más la repolarización ventricular resulta más preciso en estos casos el JT-JTc de que el QT-QTc. Ahora surge una nueva indicación para el empleo del JT-JTc. Los autores concluyeron que la superposición de LQT3 y BrS en pacientes con la mutación más común es elevada. Por lo tanto, la prueba con ajmalina representa un paso importante para descartar el potencial de superposición de BrS en estos pacientes antes

de iniciar bloqueadores de los canales de sodio para el efecto beneficioso del acortamiento QT en LQT3. Por lo tanto Luciano debes convocar los parientes de primer grado hacerles ECGs a todos y en los sospechosos eventuales realizar en ambiente hospitalario una prueba de ajmalina. Si tú precisas por no tener en el Paraguay el screening genético yo te puedo ayudar con varios grupos amigos gratis tipo Baraja, Ramón Brugada, Arhur Wilde y la Dra Li Zhang, Barajas es más adecuado porque es mejicano muy accesible y se irá a interesar. Quien sabe no te sale un trabajo lindo en una revista de alto impact factor. Si la prueba de ajmalina da positiva es posible un overlapping syndrome

Andres R. Pérez Riera

Una pregunta al foro

¿Por qué se prefiere el Nadolol a cualquier otro beta bloqueante para tratamiento del SQTl?!!

Luis Roca

Nadolol es superior a otros beta-bloqueantes en el tratamiento del QT largo y de CPVT (taquicardia ventricular polimorfa inducida por catecolaminas).

Esto se basa en algunos estudios y también en la experiencia de los centros especializados en estos pacientes.

Tuve la suerte de aprender el valor terapéutico de Nadolol hace muchos años durante mi entrenamiento en el servicio del Dr. Rosenbaum en Argentina.

Como el Nadolol corre peligro de extinción (como la quindina), se va a publicar el mes próximo un artículo sobre la necesidad de evitar que esto ocurra: ([Heart Rhythm.2017 Jan;14:e41-e44.Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?](#))

Mario González

